View Categories

Mitral Regurgitation

22 min read

Background #

Mitral regurgitation (MR) is the retrograde flow of blood from the left ventricle into the left atrium during systole due to incompetent closure of the mitral valve [1]. This volume overload increases left atrial and pulmonary pressures, eventually leading to left ventricular dilation, atrial fibrillation, pulmonary hypertension, and heart failure if untreated [2,3]. MR is the most common valvular abnormality worldwide, affecting over 2% of the total population, with a global prevalence that increases substantially with age [4,5].

Classification/Types #

By Etiology

Primary (Degenerative) MR: Intrinsic valve disease (e.g., myxomatous degeneration, mitral valve prolapse, rheumatic disease, endocarditis) [6,7].

Secondary (Functional) MR: Results from left ventricular or left atrial remodeling without organic valve disease. In ischemic or nonischemic cardiomyopathy, left ventricular dilation (regional or global) leads to papillary muscle displacement, tethering, and leaflet malcoaptation. In atrial functional MR, regurgitation occurs in patients with left atrial dilation and altered mitral annular geometry due to atrial fibrillation [8,9].

By Onset

Acute MR: Sudden onset, often due to papillary muscle rupture (myocardial infarction), endocarditis, chordae tendineae rupture, or trauma [10].

Chronic MR: Progressive valve degeneration or functional remodeling over time [11].

By Severity

Based on echocardiographic criteria [12]:

  • Mild
  • Moderate
  • Severe: Quantified using regurgitant volume ≥60 mL, effective regurgitant orifice area (EROA) ≥0.4 cm², and vena contracta width ≥7 mm

Epidemiology #

Mitral regurgitation is the most common left heart valve disease globally [13]. The global prevalence of moderate-to-severe MR is estimated at approximately 1.7% in the general population, with prevalence increasing to 9.3% in individuals over 75 years of age [14,15]. A 2025 systematic review and meta-analysis of population-based studies confirmed that MR prevalence increases significantly with age and shows gender-specific patterns [16].

Sex: Myxomatous degeneration and mitral valve prolapse are more common in women, while ischemic MR is more common in men [17,18]. The prevalence of mitral valve prolapse ranges from 2.4% to 3% in the general population, with higher rates in women [19,20].

Age: Prevalence increases progressively with age due to degenerative changes. Approximately 19% of middle-aged and older adults have MR of at least mild severity when assessed by Doppler echocardiography [21].

Geography: Degenerative MR is more common in high-income countries, where it has replaced rheumatic heart disease as the leading cause of mitral valve abnormalities [22,23]. Rheumatic MR remains prevalent in low- and middle-income countries [24].

Comorbidities: MR is often associated with hypertension, coronary artery disease, heart failure, and atrial fibrillation [25,26]. Among patients undergoing percutaneous coronary intervention, the prevalence of moderate-to-severe MR is approximately 12.4%, with significantly higher rates (28.8%) in those with heart failure [27].

In acute mitral regurgitation, a sudden volume and pressure overload occurs on an unprepared left ventricle and left atrium, resulting in an abrupt increase in left ventricular stroke work [28]. The increased preload and decreased afterload lead to elevated left atrial pressures that are transmitted to the pulmonary vasculature, causing acute pulmonary edema. Since the left atrium has not had time to adapt, compliance remains low, and marked elevations in pulmonary venous pressure occur rapidly [29].

Pathophysiology #

In chronic mitral regurgitation, compensatory mechanisms develop over time. The left ventricle undergoes eccentric hypertrophy with progressive chamber dilation to accommodate the increased preload, while the left atrium enlarges to accept the regurgitant volume [30,31]. During the compensated stage, left atrial compliance increases, allowing the left atrium to accommodate the regurgitant volume without marked pressure elevations. The ventricle maintains forward stroke volume through increased total stroke volume facilitated by the Frank-Starling mechanism [32]. However, over time, persistent volume overload leads to a positive feedback loop: ventricular dilation causes mitral annular dilation, which worsens leaflet coaptation and further increases regurgitation [33].

As the disease progresses to the decompensated stage, myocardial contractility declines, left ventricular ejection fraction decreases (though it may remain in the “normal” range of 50-60% due to the low-impedance leak into the left atrium), and left ventricular end-systolic dimensions increase [34]. The chronic volume overload eventually leads to irreversible myocardial dysfunction, elevated left atrial and pulmonary pressures, atrial fibrillation, pulmonary hypertension, and right heart failure [35,36].

Etiology #

Causes

  • Myxomatous valve degeneration (e.g., mitral valve prolapse, Barlow disease, fibroelastic deficiency)
  • Rheumatic heart disease
  • Infective endocarditis
  • Ischemic heart disease (papillary muscle rupture/dysfunction, typically involving the posteromedial papillary muscle)
  • Cardiomyopathy (dilated or hypertrophic)
  • Congenital anomalies (e.g., cleft mitral valve)
  • Mitral annular calcification
  • Chest trauma or radiation-induced heart disease
  • Connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta)

Risk Factors

  • Age >60 years
  • Coronary artery disease or prior myocardial infarction
  • History of rheumatic fever
  • Connective tissue disorders (e.g., Marfan syndrome, Ehlers-Danlos syndrome)
  • Atrial fibrillation
  • Previous endocarditis
  • Hypertension and heart failure

Clinical Presentation #

I) History (Symptoms)

  • Fatigue and reduced exercise tolerance
  • Dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea
  • Palpitations (especially with atrial fibrillation)
  • Signs of heart failure (in advanced disease): peripheral edema, weight gain
  • Acute MR: Sudden onset dyspnea, acute pulmonary edema, hypotension, cardiogenic shock

II) Physical Exam (Signs)

General Exam:

  • Patients with chronic compensated MR may appear well
  • Patients with decompensated MR or acute MR appear acutely ill with respiratory distress
  • Signs of volume overload in chronic severe MR

Vital Signs:

  • Tachycardia
  • Hypotension (in acute MR or decompensated chronic MR)
  • Tachypnea in acute decompensation

Cardiac Exam:

  • Holosystolic murmur best heard at the apex, radiating to the left axilla
  • Murmur intensity increases with handgrip or squatting (increased afterload)
  • S3 gallop (suggests volume overload)
  • Displaced, hyperdynamic apical impulse (in chronic severe MR with left ventricular dilation)
  • Mid-systolic click (in mitral valve prolapse)

Pulmonary:

  • Rales or crackles in pulmonary edema
  • Signs of pulmonary hypertension in chronic MR (right ventricular heave, loud P2)

Peripheral:

  • Peripheral edema (in right-sided heart failure)
  • Elevated jugular venous pressure (advanced disease with right heart failure)

Differential Diagnosis #

  • Mitral stenosis
  • Aortic regurgitation
  • Tricuspid regurgitation
  • Heart failure with preserved or reduced ejection fraction
  • Cardiomyopathy (dilated, hypertrophic)
  • Atrial septal defect
  • Constrictive pericarditis
  • Ventricular septal defect

Diagnostic Testing #

Initial Tests

Transthoracic Echocardiogram (TTE):

  • Confirms MR severity and mechanism
  • Assesses valve morphology, regurgitant volume, EROA, vena contracta width
  • Measures left atrial and left ventricular size
  • Evaluates left ventricular systolic function (ejection fraction)
  • Estimates pulmonary artery systolic pressure

Transesophageal Echocardiography (TEE):

  • Superior valve visualization, especially for surgical planning
  • Essential in endocarditis evaluation
  • Helpful when TTE images are suboptimal

Electrocardiogram (ECG):

  • Atrial fibrillation
  • Left atrial enlargement (P mitrale)
  • Left ventricular hypertrophy

Chest X-ray:

  • Left atrial and ventricular enlargement
  • Pulmonary vascular congestion
  • Cardiomegaly

B-type Natriuretic Peptide (BNP/NT-proBNP):

  • Elevated in decompensated MR with heart failure
  • Correlates with symptom severity and offers prognostic insights

Cardiac MRI:

  • Precise quantification of regurgitant volume and regurgitant fraction
  • Assessment of left ventricular volumes and function
  • Cardiac MRI demonstrates stronger correlation with left ventricular remodeling than echocardiography
  • Useful when echocardiographic findings are inconclusive

Cardiac Catheterization:

  • Assessment of coronary anatomy before surgical intervention
  • Hemodynamic evaluation in unclear cases
  • Direct measurement of transvalvular pressure gradients when noninvasive testing is inconclusive

Treatment #

I) Medical Management

Guideline-Directed Medical Therapy for Heart Failure: [37,38]

  • Diuretics for volume overload and symptom relief
  • Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in secondary MR with left ventricular dysfunction
  • Beta-blockers for chronic MR with left ventricular systolic dysfunction
  • Mineralocorticoid receptor antagonists in appropriate patients with heart failure

Rate Control and Anticoagulation for Atrial Fibrillation: [39,40]

  • Beta-blockers, calcium channel blockers, or digoxin for ventricular rate control
  • Oral anticoagulation for stroke prevention:
    • Warfarin (vitamin K antagonist) for patients with mechanical prosthetic valves or rheumatic mitral stenosis with atrial fibrillation
    • Direct oral anticoagulants (DOACs) are recommended as an alternative to warfarin in patients with atrial fibrillation and native valve disease (including MR) with CHA₂DS₂-VASc score ≥2, based on individual patient factors and shared decision-making [41]

Endocarditis Prophylaxis: [42]

  • Not routinely recommended for native valve disease
  • Recommended only for patients with prior endocarditis or prosthetic valves

II) Interventional/Surgical Management

Surgical Mitral Valve Repair or Replacement: [96,97,98]

Indications for intervention in primary (degenerative) MR:

  • Severe symptomatic primary MR (Class I recommendation)
  • Asymptomatic severe primary MR with:
    • Left ventricular ejection fraction ≤60% (Class I)
    • Left ventricular end-systolic dimension ≥40 mm (Class I)
    • New-onset atrial fibrillation (Class IIa)
    • Pulmonary hypertension (pulmonary artery systolic pressure >50 mm Hg) (Class IIa)

Mitral valve repair is generally preferred over replacement when feasible, as repair is associated with:

  • Lower perioperative mortality
  • Better preservation of left ventricular function
  • Lower risk of endocarditis
  • No need for long-term anticoagulation (if sinus rhythm is maintained)
  • Improved long-term survival [43,44]

Indications for intervention in secondary (functional) MR:

  • Severe secondary MR at the time of coronary artery bypass grafting (CABG) or other cardiac surgery (Class IIa recommendation in ACC/AHA guidelines) [45]
  • Guideline-directed medical therapy and cardiac resynchronization therapy (when indicated) remain the primary treatment for secondary MR [46]

Transcatheter Edge-to-Edge Mitral Valve Repair (TEER): [103,104,105]

For primary MR:

  • Severely symptomatic primary MR in patients at high or prohibitive surgical risk with favorable anatomy (Class IIa recommendation)
  • Anatomy must be suitable based on specific criteria (adequate leaflet length, appropriate pathology)

For secondary MR:

  • Patients with heart failure with reduced ejection fraction (LVEF 20-50%) and severe symptomatic secondary MR who remain symptomatic despite optimal guideline-directed medical therapy and cardiac resynchronization therapy (when indicated) (Class IIa recommendation)
  • Favorable anatomic criteria based on COAPT trial: LVEF 20-50%, left ventricular end-systolic dimension ≤70 mm, pulmonary artery systolic pressure ≤70 mm Hg
  • Must be evaluated by a multidisciplinary heart valve team [47]

Transcatheter Mitral Valve Replacement (TMVR):

  • Emerging therapy, not yet included in current guidelines as routine treatment
  • Under investigation for selected high-risk patients [48]

III) Multidisciplinary Heart Team Evaluation

All patients with severe valvular heart disease being considered for valve intervention should be evaluated by a multidisciplinary heart team, with either referral to or consultation with a Primary or Comprehensive Valve Center [49,50]. The heart team should include:

  • Cardiologists with expertise in valvular heart disease
  • Cardiac imaging specialists
  • Interventional cardiologists with training in structural heart disease
  • Cardiac surgeons experienced in valve surgery
  • Heart failure specialists (for secondary MR)
  • Cardiovascular anesthesiologists [51]

Consults #

  • Cardiology: All patients with moderate to severe MR or symptomatic patients
  • Cardiothoracic Surgery: Evaluation for mitral valve surgery in appropriate candidates
  • Interventional Cardiology/Structural Heart Disease: For transcatheter interventions (TEER, TMVR)
  • Electrophysiology: If recurrent or symptomatic atrial fibrillation, consideration for catheter ablation
  • Infectious Disease: If endocarditis suspected
  • Heart Failure Specialist: For optimization of guideline-directed medical therapy, especially in secondary MR
  • Primary Care/Internal Medicine: For chronic disease optimization and cardiovascular risk factor management

Patient Education, Counseling, Screening, and Vaccines #

Patient Education and Self-Management

  • Importance of adherence to prescribed medications and regular follow-up appointments [52]
  • Monitor for symptoms of worsening heart failure (e.g., progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema) [53]
  • Daily weight monitoring to detect fluid retention (gain of >2-3 pounds in 1 day or >5 pounds in 1 week should prompt medical evaluation) [54]
  • Sodium restriction (typically <2-3 grams per day) if volume overload is present [55]
  • Moderate physical activity is generally encouraged for asymptomatic patients; avoid excessive physical exertion in symptomatic patients [56]
  • Prompt medical attention for fever (possible endocarditis), palpitations, chest pain, or acute dyspnea [57]

Screening Recommendations

The U.S. Preventive Services Task Force (USPSTF) does not have specific recommendations for routine screening for asymptomatic valvular heart disease in the general population. However, clinical evaluation with history, physical examination, and echocardiography when indicated is recommended for patients with cardiac murmurs or symptoms suggestive of valvular disease [58].

Cardiovascular Risk Factor Screening (per USPSTF recommendations):

  • Blood pressure screening: Adults aged 18 years or older should be screened for hypertension [59]
  • Lipid disorder screening: Adults aged 40-75 years without known cardiovascular disease should be screened based on cardiovascular risk assessment [60]
  • Diabetes screening: Adults aged 35-70 years who are overweight or obese should be screened [61]
  • Atrial fibrillation screening: Based on individualized assessment; USPSTF found insufficient evidence for routine screening in asymptomatic adults [62]

Vaccinations

Vaccination recommendations are based on CDC Advisory Committee on Immunization Practices (ACIP) guidelines, as the USPSTF refers immunization recommendations to ACIP [63,64]:

Influenza Vaccine: [65,66]

  • Annual vaccination recommended for all adults
  • For adults ≥65 years: preferential use of high-dose inactivated influenza vaccine (HD-IIV3), adjuvanted inactivated influenza vaccine (aIIV3), or recombinant influenza vaccine
  • Patients with heart disease are at higher risk for influenza complications

Pneumococcal Vaccine: [67,68]

  • Adults aged ≥65 years: One dose of PCV20 or PCV21; or one dose of PCV15 followed by PPSV23 at least one year later
  • Adults aged 19-64 years with chronic heart disease: PCV15 or PCV20 or PCV21 recommended

COVID-19 Vaccine: [69,70]

  • Stay updated with COVID-19 vaccination per current CDC recommendations
  • Adults aged 19-64 years: 1 or more doses of updated vaccine
  • Adults aged ≥65 years: 2 or more doses of updated vaccine
  • Patients with cardiovascular disease are at increased risk for severe COVID-19

Tetanus-Diphtheria-Pertussis (Tdap/Td): [71]

  • One dose of Tdap, then Td booster every 10 years

Respiratory Syncytial Virus (RSV) Vaccine: [72]

  • Adults aged ≥75 years: One dose recommended
  • Adults aged 60-74 years: One dose recommended based on shared clinical decision-making for those at increased risk

Hepatitis B Vaccine: [73]

  • Universal recommendation for adults aged 19-59 years
  • Adults aged ≥60 years: Based on shared clinical decision-making

Follow-Up #

Echocardiographic Surveillance

Asymptomatic Severe Primary MR:

  • Transthoracic echocardiography annually
  • Every 6-12 months if progressive left ventricular dilation or declining ejection fraction

Asymptomatic Moderate Primary MR:

  • Transthoracic echocardiography every 1-2 years

Asymptomatic Mild MR:

  • Clinical follow-up; serial echocardiography not indicated unless clinical change

After Mitral Valve Repair or Replacement:

  • Initial post-operative echocardiography
  • Annual clinical follow-up with echocardiography as clinically indicated

References #

[1] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923

[2] Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373(9672):1382-1394. https://doi.org/10.1016/S0140-6736(09)60692-9

[3] Lazam S, Vanoverschelde JL, Tribouilloy C, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation. 2017;135(5):410-422. https://doi.org/10.1161/CIRCULATIONAHA.116.023340

[4] Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897-902. https://doi.org/10.1016/S0002-9149(98)01064-9

[5] Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. https://doi.org/10.1016/S0140-6736(06)69208-8

[6] Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1966. https://doi.org/10.1093/eurheartj/ehq222

[7] Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation. 2014;129(21):2158-2170. https://doi.org/10.1161/CIRCULATIONAHA.113.006702

[8] Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging. 2019;12(2):353-362. https://doi.org/10.1016/j.jcmg.2018.11.006

[9] Deferm S, Bertrand PB, Verhaert D, et al. Atrial functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol. 2019;73(19):2465-2476. https://doi.org/10.1016/j.jacc.2019.02.061

[10] Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008;52(5):319-326. https://doi.org/10.1016/j.jacc.2008.02.084

[11] Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation. 2012;125(13):1643-1651. https://doi.org/10.1161/CIRCULATIONAHA.111.055111

[12] Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30(4):303-371. https://doi.org/10.1016/j.echo.2017.01.007

[13] Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18(12):853-864. https://doi.org/10.1038/s41569-021-00570-z

[14] d’Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515-3522. https://doi.org/10.1093/eurheartj/ehw229

[15] Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011;8(3):162-172. https://doi.org/10.1038/nrcardio.2010.202

[16] Konstantinou DM, Velliou M, Iakovakis M, et al. Global prevalence of mitral regurgitation: a systematic review and meta-analysis of population-based studies. J Clin Med. 2025;14(8):2749. https://doi.org/10.3390/jcm14082749

[17] Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352(9):875-883. https://doi.org/10.1056/NEJMoa041451

[18] Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103(13):1759-1764. https://doi.org/10.1161/01.CIR.103.13.1759

[19] Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. https://doi.org/10.1056/NEJM199907013410101

[20] Delling FN, Rong J, Larson MG, et al. Evolution of mitral valve prolapse: insights from Framingham Heart Study. Circulation. 2016;133(17):1688-1695. https://doi.org/10.1161/CIRCULATIONAHA.115.020621

[21] Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897-902. https://doi.org/10.1016/S0002-9149(98)01064-9

[22] Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231-1243. https://doi.org/10.1016/S0195-668X(03)00201-X

[23] Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010;85(5):483-500. https://doi.org/10.4065/mcp.2009.0706

[24] Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357(5):470-476. https://doi.org/10.1056/NEJMoa065085

[25] Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. 2011;97(20):1675-1680. https://doi.org/10.1136/hrt.2011.225789

[26] Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol. 1999;34(7):2078-2085. https://doi.org/10.1016/S0735-1097(99)00474-X

[27] Zhang X, Zhang Y, Li Y, et al. Prevalence and mortality of moderate or severe mitral regurgitation among patients undergoing percutaneous coronary intervention with or without heart failure: results from CIN study with 28,358 patients. Front Cardiovasc Med. 2022;9:796447. https://doi.org/10.3389/fcvm.2022.796447

[28] Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation. 2005;112(5):745-758. https://doi.org/10.1161/CIRCULATIONAHA.104.486720

[29] Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2008;52(13):e1-142. https://doi.org/10.1016/j.jacc.2008.05.007

[30] Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: implications for management. Circulation. 2008;118(22):2298-2303. https://doi.org/10.1161/CIRCULATIONAHA.107.755942

[31] Chaput M, Handschumacher MD, Tournoux F, et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation. 2008;118(8):845-852. https://doi.org/10.1161/CIRCULATIONAHA.107.749440

[32] Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation. 1979;59(6):1218-1231. https://doi.org/10.1161/01.CIR.59.6.1218

[33] Carpentier A. Cardiac valve surgery—the “French correction”. J Thorac Cardiovasc Surg. 1983;86(3):323-337. PMID: 6887954

[34] Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation. 1999;99(3):400-405. https://doi.org/10.1161/01.CIR.99.3.400

[35] Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation. 2002;106(11):1355-1361. https://doi.org/10.1161/01.CIR.0000028933.34260.09

[36] Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996;335(19):1417-1423. https://doi.org/10.1056/NEJM199611073351902

[37] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. https://doi.org/10.1016/j.jacc.2021.12.012

[38] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368

[39] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-132. https://doi.org/10.1016/j.jacc.2019.01.011

[40] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612

[41] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation. 2017;135(25):e1159-e1195. https://doi.org/10.1161/CIR.0000000000000503

[42] Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation. 2007;116(15):1736-1754. https://doi.org/10.1161/CIRCULATIONAHA.106.183095

[43] Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. Ann Thorac Surg. 2006;82(3):819-826. https://doi.org/10.1016/j.athoracsur.2006.03.091

[44] Lazam S, Vanoverschelde JL, Tribouilloy C, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation. 2017;135(5):410-422. https://doi.org/10.1161/CIRCULATIONAHA.116.023340

[45] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923

[46] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. https://doi.org/10.1016/j.jacc.2021.12.012

[47] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923

[48] Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol. 2019;73(11):1250-1260. https://doi.org/10.1016/j.jacc.2018.12.066

[49] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923

[50] Fiorilli PN, Herrmann HC, Giri J, et al. Organization and structure of valve centers. J Am Coll Cardiol. 2019;74(13):1745-1750. https://doi.org/10.1016/j.jacc.2019.07.059

[51] Badhwar V, Rankin JS, He X, et al. Performing concomitant tricuspid valve repair at the time of mitral valve operations is not associated with increased operative mortality. Ann Thorac Surg. 2017;103(2):587-593. https://doi.org/10.1016/j.athoracsur.2016.09.016

[52] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923

[53] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147-239. https://doi.org/10.1016/j.jacc.2013.05.019

[54] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. https://doi.org/10.1016/j.jacc.2021.12.012

[55] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776-803. https://doi.org/10.1016/j.jacc.2017.04.025

[56] Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873-934. https://doi.org/10.1161/CIR.0b013e31829b5b44

[57] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3128. https://doi.org/10.1093/eurheartj/ehv319

[58] US Preventive Services Task Force. Grade Definitions. Accessed November 22, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions

[59] US Preventive Services Task Force. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2021;325(16):1650-1656. https://doi.org/10.1001/jama.2021.4987

[60] US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. https://doi.org/10.1001/jama.2022.13044

[61] US Preventive Services Task Force. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736-743. https://doi.org/10.1001/jama.2021.12531

[62] US Preventive Services Task Force. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360-367. https://doi.org/10.1001/jama.2021.23732

[63] US Preventive Services Task Force. Immunizations for Adults. Accessed November 22, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/immunizations-for-adults

[64] Centers for Disease Control and Prevention. CDC’s Advisory Committee on Immunization Practices (ACIP). Accessed November 22, 2025. https://www.cdc.gov/vaccines/acip/index.html

[65] Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 influenza season. MMWR Recomm Rep. 2024;73(5):1-25. https://doi.org/10.15585/mmwr.rr7305a1

[66] Freedman MS, Hunter P, Ault K, Kroger A. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older — United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(2):19-24. https://doi.org/10.15585/mmwr.mm7402a3

[67] Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1174-1181. https://doi.org/10.15585/mmwr.mm7137a3

[68] Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-1075. https://doi.org/10.15585/mmwr.mm6846a5

[69] Centers for Disease Control and Prevention. COVID-19 Vaccines for 2024-2025. Accessed November 22, 2025. https://www.cdc.gov/covid/vaccines/index.html

[70] Freedman MS, Hunter P, Ault K, Kroger A. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older — United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(2):19-24. https://doi.org/10.15585/mmwr.mm7402a3

[71] Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1-44. https://doi.org/10.15585/mmwr.rr6702a1

[72] Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. https://doi.org/10.15585/mmwr.mm7229a4

[73] Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. https://doi.org/10.15585/mmwr.mm7113a1

Document prepared: November 22, 2025 Version: 2.1 – Comprehensive Review with Updated Guidelines

This document incorporates the latest evidence-based guidelines from the 2020 ACC/AHA Valvular Heart Disease Guidelines, 2022 AHA/ACC/HFSA Heart Failure Guidelines, and current CDC ACIP immunization recommendations. All treatment recommendations reflect contemporary clinical practice as of 2025.

Updated on November 25, 2025